Alcon vs The Cooper Companies: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Alcon AG (ALC.SW)

Q3 20266 Aug – 2 Sep 2026

▲2▼1

Alcon Beats and Raises, but Faces New US Drug Pricing Deals

Strong Q2 results and raised guidance Alcon's second-quarter sales rose 8% to $2.8 billion, and the company raised its full-year outlook for core operating margin and earnings per share growth. This tells investors the core business is performing better than expected, which supports a higher share price.
This is the most direct positive driver of Alcon's value this period.
RxSight collaboration expands premium lens offerings Alcon and RxSight are teaming up on adjustable intraocular lenses, combining RxSight's technology with Alcon's global sales reach. This opens a new premium product line for Alcon and validates its strategy in advanced eye surgery, a positive for future growth.
It shows a new growth avenue that can lift Alcon's long-term sales and pricing power.
Alcon joins US most-favored-nation drug pricing deals Alcon agreed to lower prices on outpatient drugs for state Medicaid programs to match international levels, in exchange for relief from import tariffs. This could pressure Alcon's US pricing and revenue, though the tariff relief and voluntary state participation soften the blow.
It is a new regulatory headwind that directly affects Alcon's pricing and profitability.

August 20266 Aug – 2 Sep 2026

▲2▼1

Alcon Beats and Raises, but Faces New US Drug Pricing Deals

Strong Q2 results and raised guidance Alcon's second-quarter sales rose 8% to $2.8 billion, and the company raised its full-year outlook for core operating margin and earnings per share growth. This tells investors the core business is performing better than expected, which supports a higher share price.
This is the most direct positive driver of Alcon's value this period.
RxSight collaboration expands premium lens offerings Alcon and RxSight are teaming up on adjustable intraocular lenses, combining RxSight's technology with Alcon's global sales reach. This opens a new premium product line for Alcon and validates its strategy in advanced eye surgery, a positive for future growth.
It shows a new growth avenue that can lift Alcon's long-term sales and pricing power.
Alcon joins US most-favored-nation drug pricing deals Alcon agreed to lower prices on outpatient drugs for state Medicaid programs to match international levels, in exchange for relief from import tariffs. This could pressure Alcon's US pricing and revenue, though the tariff relief and voluntary state participation soften the blow.
It is a new regulatory headwind that directly affects Alcon's pricing and profitability.

Latest6 Aug – 2 Sep 2026

▲2▼1

Alcon Beats and Raises, but Faces New US Drug Pricing Deals

Strong Q2 results and raised guidance Alcon's second-quarter sales rose 8% to $2.8 billion, and the company raised its full-year outlook for core operating margin and earnings per share growth. This tells investors the core business is performing better than expected, which supports a higher share price.
This is the most direct positive driver of Alcon's value this period.
RxSight collaboration expands premium lens offerings Alcon and RxSight are teaming up on adjustable intraocular lenses, combining RxSight's technology with Alcon's global sales reach. This opens a new premium product line for Alcon and validates its strategy in advanced eye surgery, a positive for future growth.
It shows a new growth avenue that can lift Alcon's long-term sales and pricing power.
Alcon joins US most-favored-nation drug pricing deals Alcon agreed to lower prices on outpatient drugs for state Medicaid programs to match international levels, in exchange for relief from import tariffs. This could pressure Alcon's US pricing and revenue, though the tariff relief and voluntary state participation soften the blow.
It is a new regulatory headwind that directly affects Alcon's pricing and profitability.

The Cooper Companies, Inc (COO)

Q3 20269 Sep – 18 Sep 2026

▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.
This is the main new event that drove the stock down this period.
Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.
This is a new capital action that partially offsets the negative guidance news.
Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.
This is the latest new development that could change the company's direction and stock price.

September 20269 Sep – 18 Sep 2026

▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.
This is the main new event that drove the stock down this period.
Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.
This is a new capital action that partially offsets the negative guidance news.
Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.
This is the latest new development that could change the company's direction and stock price.

Latest9 Sep – 18 Sep 2026

▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.
This is the main new event that drove the stock down this period.
Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.
This is a new capital action that partially offsets the negative guidance news.
Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.
This is the latest new development that could change the company's direction and stock price.